Inicio / Oncología / Abstracts de oncología / KMT2D Deficiency Impairs…

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

0 / 5 (0 votos)
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

Cancer Cell

Fecha de publicación: 2 April 2020

DOI: https://doi.org/10.1016/j.ccell.2020.03.005

Autores: Hunain Alam, Ming Tang, Mayinuer Maitituoheti, Laura Baseler, Kunal Rai, Min Gyu Lee

Background: Epigenetic modifiers frequently harbor loss-of-function mutations in lung cancer, but their tumor-suppressive roles are poorly characterized. Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.